Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He did his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent three decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of hematology/oncology and Professor of Medicine at the University of Tennessee Health Science center from 2012-2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees including breast cancer.
Dr. Schwartzberg has published nearly 300 peer reviewed manuscripts, book chapters and monographs. He is founding editor in chief of the Elsevier website PracticeUpdate Oncology and founding editor in chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine and patient reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Positions:
Medical Director, West Cancer Center, Memphis, Tennessee
Chief Medical Officer, OneOncology
Degrees:
State University of New York, BA and MS
New York Medical College, MD, FACP
Postgraduate Training:
Intern, North Shore University Hospital, Manhasset, NY
Fellow in medical oncology/hematology, Memorial Sloan-Kettering Cancer Center
Board Certifications:
Medical oncology
Hematology
Clinical Interests:
Medical oncology/hematology
Disclosures
He is a consultant for Amgen, Pfizer, Helsinn, Genentech, BMS, Myriad, AstraZeneca, Spectrum, and Napo.
He is also on the advisory board for Genomic Health Research Funding (Institution): Amgen and DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Addition of Everolimus Did Not Prolong Overall Survival in HR+ HER2-Negative Advanced Breast Cancer
- PIK3CA Mutations Associated With Lower Response in HER2-Positive Breast Cancer
- Long-Term Follow-Up of Breast Cancer Patients With Negative Node and No Axillary Dissection
- Lapatinib With Trastuzumab for HER2-Positive Early Breast Cancer
- PI3K/AKT Mutations Do Not Seem to Impact Residual Risk After Endocrine Therapy
- PALB2 Mutations Increase Breast Cancer Risk
- Safety and Practicality of Breast Conservation Surgery in Large Tumors
- Weekly Topotecan Plus Ziv-Aflibercept in Platinum-Treated Small-Cell Lung Cancer
- Less Frequent Zoledronic Acid an Option in Metastatic Breast Cancer
- Adjuvant Doxorubicin Plus Cyclophosphamide vs Paclitaxel in Breast Cancer